InCarda Gets $30m Closer To Inhalable AF Drug/Device Therapy

 
• By Joseph Haas
  
Atrial fibrillation and normal or abnormal heart rate rythm as a cardiac disorder as a human organ with healthy and unhealthy ecg monitoring in a 3D illustration style.
InCarda ultimately hopes to offer a major change in atrial fibrillation therapy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business